NCT05738161 (MACOCUC-01) is a Phase 1 clinical trial of Magrolimab in Advanced Urothelial Carcinoma, sponsored by Insel Gruppe AG, University Hospital Bern.

Who is sponsoring NCT05738161?

NCT05738161 is sponsored by Insel Gruppe AG, University Hospital Bern.

What drugs are being tested in NCT05738161?

Interventions in NCT05738161: Magrolimab, Cisplatin, Gemcitabine.

What condition does NCT05738161 study?

NCT05738161 studies Advanced Urothelial Carcinoma.

Is NCT05738161 still recruiting?

NCT05738161 is currently withdrawn. Last updated 5 July 2024.

Last reviewed 2024-07-05 · How we verify

NCT05738161: MACOCUC-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma

Withdrawn Phase 1 Last updated 5 July 2024

What this trial tests

Phase 1 trial testing Magrolimab in Advanced Urothelial Carcinoma. Withdrawn.

Timeline

21 June 2023

Primary endpoint
27 February 2024

27 February 2024

Quick facts

Lead sponsor	Insel Gruppe AG, University Hospital Bern
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	21 June 2023
Primary completion	27 February 2024
Estimated completion	27 February 2024

Drugs / interventions tested

Magrolimab — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Advanced Urothelial Carcinoma — all drugs for Advanced Urothelial Carcinoma →

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

18 and older, any sex, with Advanced Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In their "Magrolimab" research project, the investigators want to find out whether the new drug Magrolimab in combination with conventional chemotherapy is well tolerated and whether survival or progression-free survival improves.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Association of CD47 Expression with Clinicopathologic Characteristics and Survival Outcomes in Muscle Invasive Bladder Cancer.
Myint ZW, Chahine Z, Jayswal R, Bachert E, et al · · 2023 · cited 6× · PMID 37373873 · DOI 10.3390/jpm13060885
Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment.
Zhu G, Wan X, Wu W, Jia L, et al · · 2025 · cited 3× · PMID 40657202 · DOI 10.1002/smsc.202400479

Verify or expand the search:

Other trials of Magrolimab

Trials testing the same drug.

NCT05367401 — A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants · Phase 1, PHASE2 · withdrawn
NCT05823480 — Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS · Phase 1 · withdrawn
NCT05829434 — Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS · Phase 2 · withdrawn
NCT05807126 — Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of · Phase 1 · withdrawn
NCT06046482 — Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous C · Phase 2 · terminated

Other recruiting trials for Advanced Urothelial Carcinoma

Currently open trials in the same condition.

NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
NCT07241793 — Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metast · Phase 2 · recruiting
NCT07063758 — A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma · active not recruiting
NCT06904573 — Probiotics in Advanced Urothelial Carcinoma · Phase 2 · recruiting
NCT06639347 — A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma · Phase 1, PHASE2 · recruiting

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05738161 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
Last refreshed: 5 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05738161.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing